| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
St. Vincent’s Institute of Medical Research and The University of Melbourne, Department of Medicine, St. Vincent’s Hospital, Fitzroy, Victoria 3065, Australia
Address all correspondence and requests for reprints to: Matthew T. Gillespie, St. Vincent’s Institute of Medical Research, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia. E-mail: m.gillespie{at}medicine.unimelb.edu.au
 |
Abstract |
|---|
 Top Abstract |
|---|
Received May 13, 1998.
This article has been cited by other articles:
 |
|
 |
|
  R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Jun, Y.-M. Kang, H.-R. Lee, S.-H. Lee, and B.-K. Choi Highly Conserved Surface Proteins of Oral Spirochetes as Adhesins and Potent Inducers of Proinflammatory and Osteoclastogenic Factors Infect. Immun., June 1, 2008; 76(6): 2428 - 2438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. M. Sutton, X. Zhang, D. R. Dowd, Y. P. Kharode, B. S. Komm, and P. N. MacDonald Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in Mice Mol. Endocrinol., June 1, 2008; 22(6): 1370 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Pickard, A. B. Hodsman, L. J. Fraher, and P. H. Watson Type 1 Parathyroid Hormone Receptor (PTH1R) Nuclear Trafficking: Association of PTH1R with Importin {alpha}1 and {beta} Endocrinology, July 1, 2006; 147(7): 3326 - 3332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lee, J. S. Finkelstein, M. Miller, S. J. Comeaux, R. I. Cohen, and B. Z. Leder Effects of Selective Testosterone and Estradiol Withdrawal on Skeletal Sensitivity to Parathyroid Hormone in Men J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Young, N. Mikhalkevich, Y. Yan, D. Chen, and W.-p. Zheng Differential Regulation of Osteoblast Activity by Th Cell Subsets Mediated by Parathyroid Hormone and IFN-{gamma} J. Immunol., December 15, 2005; 175(12): 8287 - 8295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lossdorfer, W. Gotz, and A. Jager PTH(1-34) Affects Osteoprotegerin Production in Human PDL Cells in vitro J. Dent. Res., July 1, 2005; 84(7): 634 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Normanno, A De Luca, D Aldinucci, M R Maiello, M Mancino, A D'Antonio, R De Filippi, and A Pinto Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis Endocr. Relat. Cancer, June 1, 2005; 12(2): 471 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nataf, A. Anginot, C. Vuaillat, L. Malaval, N. Fodil, E. Chereul, J.-B. Langlois, C. Dumontel, G. Cavillon, C. Confavreux, et al. Brain and Bone Damage in KARAP/DAP12 Loss-of-Function Mice Correlate with Alterations in Microglia and Osteoclast Lineages Am. J. Pathol., January 1, 2005; 166(1): 275 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Buxton, W. Yao, and N. E. Lane Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34) J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3332 - 3336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Onyia, R. J. S. Galvin, Y. L. Ma, D. L. Halladay, R. R. Miles, X. Yang, T. Fuson, R. L. Cain, Q. Q. Zeng, S. Chandrasekhar, et al. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 369 - 379. [Abstract] [Full Text]
|
|
|
|
 |
|
 U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text]
|
|
|
|
|
|
A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, and N. Horiuchi Leptin Corrects Increased Gene Expression of Renal 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase and -24-Hydroxylase in Leptin-Deficient, ob/ob Mice Endocrinology, March 1, 2004; 145(3): 1367 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, J.-T. Woo, N. Takahashi, and K. Nagai Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation J. Immunol., February 15, 2004; 172(4): 2504 - 2510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Fan, E. Roy, L. Zhu, T. C. Murphy, C. Ackert-Bicknell, C. M. Hart, C. Rosen, M. S. Nanes, and J. Rubin Nitric Oxide Regulates Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin Expression in Bone Marrow Stromal Cells Endocrinology, February 1, 2004; 145(2): 751 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Bergh, Y. Xu, and M. C. Farach-Carson Osteoprotegerin Expression and Secretion Are Regulated by Calcium Influx through the L-Type Voltage-Sensitive Calcium Channel Endocrinology, January 1, 2004; 145(1): 426 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chiusaroli, A. Maier, M. C. Knight, M. Byrne, L. M. Calvi, R. Baron, S. M. Krane, and E. Schipani Collagenase Cleavage of Type I Collagen Is Essential for Both Basal and Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor-Induced Osteoclast Activation and Has Differential Effects on Discrete Bone Compartments Endocrinology, September 1, 2003; 144(9): 4106 - 4116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zou, A. Amcheslavsky, and Z. Bar-Shavit CpG Oligodeoxynucleotides Modulate the Osteoclastogenic Activity of Osteoblasts via Toll-like Receptor 9 J. Biol. Chem., May 2, 2003; 278(19): 16732 - 16740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-K. Choi, H. J. Lee, J. H. Kang, G. J. Jeong, C. K. Min, and Y.-J. Yoo Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide of Treponema denticola Infect. Immun., January 1, 2003; 71(1): 226 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gurlek, M. R. Pittelkow, and R. Kumar Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1{alpha},25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation Endocr. Rev., December 1, 2002; 23(6): 763 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamashita, S. Okada, K. Higashio, Y.-i. Nabeshima, and M. Noda Double Mutations in Klotho and Osteoprotegerin Gene Loci Rescued Osteopetrotic Phenotype Endocrinology, December 1, 2002; 143(12): 4711 - 4717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae J. Immunol., September 15, 2002; 169(6): 3353 - 3362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Geoffroy, M. Kneissel, B. Fournier, A. Boyde, and P. Matthias High Bone Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells of the Osteoblastic Lineage Mol. Cell. Biol., September 1, 2002; 22(17): 6222 - 6233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Peleg, M. Uskokovic, A. Ahene, B. Vickery, and Z. Avnur Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats Endocrinology, May 1, 2002; 143(5): 1625 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers TNF{alpha} Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL Endocrinology, March 1, 2002; 143(3): 1108 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Coen, P. Ballanti, A. Balducci, S. Calabria, M. S. Fischer, L. Jankovic, M. Manni, M. Morosetti, E. Moscaritolo, D. Sardella, et al. Serum osteoprotegerin and renal osteodystrophy Nephrol. Dial. Transplant., February 1, 2002; 17(2): 233 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pettit, H. Ji, D. von Stechow, R. Muller, S. R. Goldring, Y. Choi, C. Benoist, and E. M. Gravallese TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis Am. J. Pathol., November 1, 2001; 159(5): 1689 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U Feige Osteoprotegerin Ann Rheum Dis, November 1, 2001; 60(90003): iii81 - 84. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D. L. Lacey, and C. R. Dunstan OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats Endocrinology, October 1, 2001; 142(10): 4295 - 4304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Watkins, Y. Li, and M. F. Seifert Nutraceutical Fatty Acids as Biochemical and Molecular Modulators of Skeletal Biology J. Am. Coll. Nutr., October 1, 2001; 20(90005): 410S - 416. [Abstract] [Full Text]
|
|
|
|
|
|
Y. L. Ma, R. L. Cain, D. L. Halladay, X. Yang, Q. Zeng, R. R. Miles, S. Chandrasekhar, T. J. Martin, and J. E. Onyia Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation Endocrinology, September 1, 2001; 142(9): 4047 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamagishi, E. Otsuka, and H. Hagiwara Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis Endocrinology, August 1, 2001; 142(8): 3632 - 3637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saika, D. Inoue, S. Kido, and T. Matsumoto 17{beta}-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-{{alpha}} Endocrinology, June 1, 2001; 142(6): 2205 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert Omega-3 Polyunsaturated Fatty Acids and Skeletal Health Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Han, S. J. Choi, N. Kurihara, M. Koide, Y. Oba, and G. D. Roodman Macrophage inflammatory protein-1{alpha} is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor {kappa}B ligand Blood, June 1, 2001; 97(11): 3349 - 3353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Horwood, J. Elliott, T. J. Martin, and M. T. Gillespie IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro J. Immunol., April 15, 2001; 166(8): 4915 - 4921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O. Oyajobi, D. M. Anderson, K. Traianedes, P. J. Williams, T. Yoneda, and G. R. Mundy Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {{kappa}}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy Cancer Res., March 1, 2001; 61(6): 2572 - 2578. [Abstract] [Full Text]
|
|
|
|
|
|
M. Takami, N. Takahashi, N. Udagawa, C. Miyaura, K. Suda, J.-T. Woo, T. J. Martin, K. Nagai, and T. Suda Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-{{kappa}}B Ligand and Osteoprotegerin in Osteoblasts Endocrinology, December 1, 2000; 141(12): 4711 - 4719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grcevic, S.-K. Lee, A. Marusic, and J. A. Lorenzo Depletion of CD4 and CD8 T Lymphocytes in Mice In Vivo Enhances 1,25-Dihydroxyvitamin D3-Stimulated Osteoclast-Like Cell Formation In Vitro by a Mechanism That Is Dependent on Prostaglandin Synthesis J. Immunol., October 15, 2000; 165(8): 4231 - 4238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. GARDINER, P. A. BALDOCK, G. P. THOMAS, N. A. SIMS, N. K. HENDERSON, B. HOLLIS, C. P. WHITE, K. L. SUNN, N. A. MORRISON, W. R. WALSH, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage FASEB J, October 1, 2000; 14(13): 1908 - 1916. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864. [Abstract] [Full Text]
|
|
|
|
|
|
N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, M. T. Gillespie, T. J. Martin, K. Higashio, et al. Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function Endocrinology, September 1, 2000; 141(9): 3478 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Otsuka, Y. Kato, S. Hirose, and H. Hagiwara Role of Ascorbic Acid in the Osteoclast Formation: Induction of Osteoclast Differentiation Factor with Formation of the Extracellular Collagen Matrix Endocrinology, August 1, 2000; 141(8): 3006 - 3011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text]
|
|
|
|
|
|
L. Huang, J. Xu, D. J. Wood, and M. H. Zheng Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Giant Cell Tumor of Bone : Possible Involvement in Tumor Cell-Induced Osteoclast-Like Cell Formation Am. J. Pathol., March 1, 2000; 156(3): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Itonaga, A Sabokbar, D W Murray, and N A Athanasou Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages Ann Rheum Dis, January 1, 2000; 59(1): 26 - 31. [Abstract] [Full Text]
|
|
|
|
|
|
R. Okazaki, M. Toriumi, S. Fukumoto, M. Miyamoto, T. Fujita, K. Tanaka, and Y. Takeuchi Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro Endocrinology, November 1, 1999; 140(11): 5060 - 5065. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Thomas, T. A. Guise, J. J. Yin, J. Elliott, N. J. Horwood, T. J. Martin, and M. T. Gillespie Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation Endocrinology, October 1, 1999; 140(10): 4451 - 4458. [Abstract] [Full Text]
|
|
|
|
|
|
A. Grey, M.-A. Mitnick, U. Masiukiewicz, B.-H. Sun, S. Rudikoff, R. L. Jilka, S. C. Manolagas, and K. Insogna A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo Endocrinology, October 1, 1999; 140(10): 4683 - 4690. [Abstract] [Full Text]
|
|
|
|
|
|
S.-K. Lee and J. A. Lorenzo Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell Formation Endocrinology, August 1, 1999; 140(8): 3552 - 3561. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. G. Raisz Physiology and Pathophysiology of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1353 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Collin-Osdoby, L. Rothe, F. Anderson, M. Nelson, W. Maloney, and P. Osdoby Receptor Activator of NF-kappa B and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis J. Biol. Chem., June 1, 2001; 276(23): 20659 - 20672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhou, V. Kartsogiannis, Y. S. Hu, J. Elliott, J. M. W. Quinn, W. J. McKinstry, M. T. Gillespie, and K. W. Ng A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation J. Biol. Chem., April 27, 2001; 276(18): 14916 - 14923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Nakchbandi, E. E. Weir, K. L. Insogna, W. M. Philbrick, and A. E. Broadus Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade PNAS, June 20, 2000; 97(13): 7296 - 7300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Shevde, A. C. Bendixen, K. M. Dienger, and J. W. Pike Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression PNAS, July 5, 2000; 97(14): 7829 - 7834. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||
